Beatrice Casadei
Overview
Explore the profile of Beatrice Casadei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Argnani L, Casadei B, Zinzani P
Blood Cancer J
. 2025 Mar;
15(1):33.
PMID: 40055342
No abstract available.
2.
Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Ann Hematol
. 2025 Mar;
PMID: 40025210
Immune checkpoint inhibitors (CPIs) emerged as an effective and safe therapeutic option for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients lose their response to CPIs. To...
3.
Casadei B, Argnani L, Broccoli A, Cantelli M, Gugliotta G, Gentilini M, et al.
Blood Adv
. 2025 Feb;
PMID: 39993241
No abstract available.
4.
Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S, et al.
Transplant Cell Ther
. 2025 Jan;
PMID: 39870308
Background: Anti-CD19 CAR T-cells have revolutionized outcomes in relapsed/refractory large B-cell lymphomas. Long-term follow-up underscored the role of hematological toxicity in nonrelapse mortality, largely driven by infections, leading to the...
5.
De Matteis S, Del Coco L, Castro F, Giudetti A, Casadei B, Iannotta F, et al.
Haematologica
. 2024 Dec;
PMID: 39704157
Plasma metabolomics analysis was performed on 44 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r/B-NHL) infused with approved CD19.CAR-T cell products at the time of pre-lymphodepletion (PLD) and at day +1,...
6.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J
. 2024 Nov;
14(1):197.
PMID: 39511146
No abstract available.
7.
Han J, Koh M, Boussi L, Sorial M, McCabe S, McCabe S, et al.
Blood Adv
. 2024 Oct;
9(3):583-602.
PMID: 39481087
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural...
8.
Bramanti S, Mannina D, Chiappella A, Casadei B, De Philippis C, Giordano L, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):32-38.
PMID: 39384870
The optimization of bridging regimen before chimeric antigen receptor (CAR)-T cell therapy in diffuse large B-cell lymphoma (DLBCL) may impact CAR-T efficacy and outcome. This retrospective study evaluates CAR-T outcome...
9.
Mazzoni C, Argnani L, Casadei B, Broccoli A, Gabrielli G, Fabbri N, et al.
Eur J Haematol
. 2024 Sep;
114(1):70-78.
PMID: 39295142
First-line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional...
10.
Casadei B, Conti G, Barone M, Turroni S, Guadagnuolo S, Broccoli A, et al.
Hematol Oncol
. 2024 Aug;
42(5):e3301.
PMID: 39104142
Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD-L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To...